Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VCT220 + repaglinide + rosuvastatin + digoxin
- Development stage
- Unknown
- Lead developer
- vincentage
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VCT220 + repaglinide + rosuvastatin + digoxin is a drug combination utilized in a Phase I clinical trial to evaluate the pharmacokinetic drug-drug interactions (DDI) of VCT220. VCT220 (also known as CX11) is an investigational, orally administered small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist developed by Vincentage Pharma for the treatment of obesity and overweight conditions. In this specific study, VCT220 is co-administered with three probe drugs: repaglinide (a substrate for CYP2C8 and CYP3A4), rosuvastatin (a substrate for OATP1B1, OATP1B3, and BCRP), and digoxin (a substrate for P-glycoprotein). The study aims to determine if VCT220 affects the absorption, distribution, metabolism, or excretion of these drugs, which is essential for understanding the safety profile and potential for metabolic interactions in patients with comorbid cardiometabolic conditions.
- Other names
- VCT220 PK Interactions in Healthy, Overweight, and Obese Subjects
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)KATP channel (ATP-sensitive potassium channel)GLP1R (GLP-1R)
Beyond the preview
Go deeper on VCT220 + repaglinide + rosuvastatin + digoxin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VCT220 + repaglinide + rosuvastatin + digoxin.